Type I CALR mutations, but not type II, activate the inositol-requiring enzyme 1α (IRE1α)/X-box binding protein 1 (XBP1) pathway of the unfolded protein response, driving the development of myeloproliferative neoplasms.5 Here, CALR is linked to myeloproliferative disorder.